Reproductive scientists Key immune cells to attack deadly brain cancer

0
Share

Scientists have published a new study detailing the use of immune cells promoting the tumor to attack an aggressive and often fatal form of brain cancer. The work consists of “reprogramming” these cells so that they pass from the protection of cerebral tumors to attack them. Researchers note that some of the mice involved in the study not only rejected brain tumors, but also long-term immunity against them.

The study, which comes from Massachusetts General Hospital and other research institutions in Boston, focused specifically on glioblastomas, a type of aggressive and mortal cancer, including treatment-resistant. Researchers note that a category of drugs called immune control points (ICB) is not an effective way to treat this type of cancer.

The reason is that, despite the ICBS triggering inactive immune cells to attack the cancer cells while leaving healthy tissues mainly intact, glioblastomas escape this treatment by creating their microenvironment with tumor, which takes on the immune cells, the Proteins and blood vessels and use them to promote growth tumor.

The result is a blockage of the immune cells that attack the tumor while allowing regulatory T cells (Tregs), which are immune cells that promote the growth of the tumor. Scientists have found that they could target these tightens accumulated in the cancer tumor and reprogram them to “reprogram” to attack the cancer cells they are originally protected.

“Because the tregies already present in these tumors can be reprogrammed, this strategy does not rely on the additional recruitment of anti-tumor immune cells – another barrier frequent for successful immunotherapy in brain tumors,” said Rakesh K . Jain, Ph.D. researchers behind the new study.

Research involved mice with human glioblastomas, paving the way for potential future means to treat this deadly form of brain cancer in humans.